M&A Deal Summary |
|
|---|---|
| Date | 2023-10-05 |
| Target | Orchard Therapeutics |
| Sector | Life Science |
| Buyer(s) | Kyowa Kirin |
| Deal Type | Add-on Acquisition |
| Deal Value | 478M USD |
| Advisor(s) | Guggenheim Securities (Financial) Goodwin Procter Slaughter and May (Legal) |
SEARCH BY
Kyowa Kirin is a global specialty pharmaceutical company (J-GSP) that creates innovative medical solutions utilizing the latest biotechnology. The company applies cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including nephrology, oncology, immunology/allergy, and nurology. Kyowa Kirin is based in Tokyo.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: United Kingdom M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |